Featuring perspectives from Dr Christine L Hann and Dr Jacob Sands, including the following topics: Introduction: Biopharmacology of Small Cell Lung Cancer — "Wildfire sparked in dry grass" (0:00) Limited-Stage Disease (9:22) Extensive-Stage Disease (16:23) Paraneoplastic Syndromes — Lambert-Eaton Myasthenic Syndrome (23:54) Bispecific T-Cell Engagers — Tarlatamab (30:00) Antibody-Drug Conjugates — Ifinatamab Deruxtecan (39:19) Other Novel Agents — Alisertib, Chimeric Antigen Receptor T-Cell The...
Jun 09, 2026•59 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 1: Limited-Stage Small Cell Lung Cancer (SCLC); First-Line and Maintenance Therapy for Extensive-Stage SCLC — Jacob Sands, MD CME information and select publications
Jun 09, 2026•32 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 2: Management of Relapsed/Refractory SCLC; Promising Investigational Agents and Strategies — Christine L Hann, MD, PhD CME information and select publications
Jun 08, 2026•31 min
Featuring perspectives from Prof Thomas Powles, including the following topics: Circulating tumor DNA (ctDNA) analyses with adjuvant nivolumab for MIBC in the CheckMate 274 study (0:00) Use of ctDNA to guide response-adapted bladder preservation for patients with MIBC (2:27) ctDNA response-adapted treatment de-escalation for patients with metastatic urothelial carcinoma: The CT-READ trial (10:26) Emerging data and studies regarding urinary tumor DNA (18:04) CME information and select publication...
Jun 05, 2026•23 min
Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics: Introduction (0:00) Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30) Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39) Tolerability and Other Practical Considerations with Novel Investigational ADCs in Advanced Gynecologic Cancers — Dr Monk (1:04:58)...
Jun 03, 2026•1 hr 31 min
Interview conducted with Prof Bernd Kasper on March 5, 2026, by Dr Neil Love, including the following topics: Current management of desmoid tumors: A review from the Desmoid Tumor Working Group (0:00) Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the Phase III DeFi trial (8:26) Phase IV trial of nirogacestat in adult premenopausal women with desmoid tumors (17:35) CME information and select publications here ....
Jun 02, 2026•23 min
Proceedings from a webinar on April 16, 2026, moderated by Dr Neil Love, including the following topics: Introduction: Research To Practice Paper of the Year! (0:00) Checkpoint Inhibitors for Localized Microsatellite Instability-High Tumors (11:12) Circulating Tumor DNA Assays (21:58) Checkpoint Inhibitors for Metastatic Disease (38:32) CME information and select publications...
May 28, 2026•59 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Arvind Dasari, MD, MS CME information and select publications
May 28, 2026•36 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Recent Advances in the Management of Metastatic CRC (mCRC) — Anwaar Saeed, MD CME information and select publications
May 28, 2026•39 min
Interview conducted on March 11, 2026, by Dr Neil Love, including the following topics: Circulating tumor DNA (ctDNA)-guided adjuvant therapy with atezolizumab for muscle-invasive bladder cancer (MIBC) (0:00) Use of ctDNA in guiding systemic treatment selection for patients with urothelial bladder cancer (10:03) ctDNA analyses with perioperative durvalumab for MIBC in the Phase III NIAGARA study (16:51) New research advances in the monitoring and management of urothelial bladder cancer (22:21) C...
May 27, 2026•30 min
Proceedings from a webinar on March 11, 2026, moderated by Dr Neil Love, including the following topics: Introduction: I think I missed that day in med school (BTK biology) (0:00) First-Line Treatment (11:40) Relapsed/Refractory Disease (46:35) CME information and select publications...
May 24, 2026•59 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 2: Emerging BTK Inhibitor-Based Combination Approaches in CLL — Jennifer R Brown MD, PhD CME information and select publications...
May 24, 2026•29 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 1: Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Newly Diagnosed and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) — Wojciech Jurczak MD, PhD CME information and select publications...
May 24, 2026•20 min
Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics: Introduction (0:00) Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59) Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53) Other Novel Agents and Strategies for Advanced Ovarian Cancer — Dr Olawaiye (46:40) Diagnosis and Management of Adverse Events Assoc...
May 21, 2026•1 hr 28 min
Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer...
May 20, 2026•8 min
Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surrounding toxicities associated with PARP inhibitors (15:25) Potential role of saruparib; evolving nomencla...
May 16, 2026•52 min
Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from ...
May 16, 2026•27 min
Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25:18) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Be...
May 14, 2026•1 hr 30 min
Featuring an interview with Dr Nikhil I Khushalani, including the following topics: Overview of nonmelanoma skin cancers (0:00) Systemic therapy for nonmelanoma skin cancers (12:11) Immune checkpoint inhibitors for special patient populations (20:30) Hedgehog inhibitors for basal cell carcinoma (32:14) New developments in therapy for nonmelanoma skin cancers (38:52) Case: A man in his early 70s with cutaneous squamous cell carcinoma receives cemiplimab (43:41) Case: A man in his mid 70s with a h...
May 07, 2026•1 hr 4 min
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58) Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant...
May 02, 2026•18 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO CME information and select publications
Apr 30, 2026•29 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information and select publications...
Apr 30, 2026•28 min
Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics: Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00) Second-Line Treatment for Metastatic Breast Cancer (16:01) First-Line Therapy for Metastatic Disease (33:19) Adjuvant Therapy (35:26) Toxicity, Quality of Life (47:59) New Directions (55:22) CME information and select publications...
Apr 30, 2026•57 min
Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics: Introduction: Genomics of EGFR (and HER2) (0:00) Metastatic Disease (9:30) Localized Disease (30:22) EGFR Exon 20 Insertion Mutations (46:57) New Agents (54:20) CME information and select publications
Apr 27, 2026•57 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD CME information and select publications
Apr 27, 2026•26 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) — Helena Yu, MD CME information and select publications
Apr 27, 2026•30 min
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME informati...
Apr 25, 2026•17 min
Featuring perspectives from Dr Andrew J Armstrong and Dr Scott T Tagawa, including the following topics: Introduction: Evolution of the Prostate Cancer Model; Prostate Cancer Working Group 4 (PCWG4) (0:00) Hormonal Therapy (5:48) Chemotherapy (Docetaxel) (26:38) PARP Inhibition (29:49) Radioligand Therapy (36:56) New Agents (43:37) CME information and select publications...
Apr 23, 2026•58 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Scott T Tagawa, MD, MS CME information and select publications
Apr 23, 2026•25 min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Andrew J Armstrong, MD, ScM CME information and select publications
Apr 23, 2026•24 min
